10 Reasons You Should Invest in Companion Diagnostics | Diaceutics

10 Reasons You Should Invest in Companion Diagnostics

June 10th, 2016


Companion diagnostics are diagnostic tests that provide information to guide the use of a corresponding therapy. These days, the ‘one therapy fits all’ approach to medicine has been demonstrated to be insufficient. Trial and error is often used to select a therapy for a specific person. Companion diagnostics aim to eliminate this by identifying patients who will particularly benefit from or, in contrast, be at an enhanced risk from a certain therapy, and also to monitor treatment response.

Here are ten reasons you should put resources into companion diagnostics:

  1. The FDA may not approve some therapies without a companion diagnostic, or may require one to be created subsequently in which case time is of essence.
  2. Companion diagnostics allow dosage to be tailored to a specific patient by monitoring treatment response. This prevents over or under dosing and improves clinical results.
  3. Eliminating the trial and error factor when choosing which treatment for a particular patient saves time, money and lives. It also reduces the risk of malpractice suits being filed if the ‘wrong’ therapy is given.
  4. Companion diagnostics allow the selection of subjects most likely to be helped by clinical trials and can thus speed a therapy through review and approval.
  5. The system also facilitates the approval of therapies which might only help a small number of patients. By identifying therapies that help people with, for example, a specific mutation, these therapies can be brought to market faster and save lives.
  6. In some cases, adding a companion diagnostic can broaden the use of a therapy. For example, Gleevec, a therapy used for chronic myeloid leukemia, was initially approved only for later stages. However, the introduction of a diagnostic allowed its approval for some patients in early stages of the disease.
  7. The use of companion diagnostics may prevent therapy recall by identifying individuals who are likely to have a severe reaction, allowing the therapy to continue being used by the majority of patients.
  8. therapy developers, although not required to, have started offering substantial subsidies and royalties to companies developing diagnostic kits.
  9. Insurance companies and other payers may introduce a requirement for diagnostic tests before paying for therapies that are known to only benefit a subset of patients or for those that could have severe side effects.
  10. In the future, genome screening using computers may allow a doctor to select from a ‘library’ of therapies to get the best results for their patient, reducing costs substantially.

Personalized medicine is part of todays healthcare, and companion diagnostics are an important part of it.


Launch Planner Free Demo

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications